- The 2021 China Pharmaceutical CMC Industry Chain Technology Exchange and Entrepreneur Scientist Summit Forum will be held in Guangzhou from May 24 to May 25 to provide enterprises with a comprehensive exchange platform to showcase their professional technology and high-quality products. Chengdu Shengnuo Biotech was invited to participate in this forum.
- 2021 China Pharmaceutical CMC Industry Chain Technology Exchange and Entrepreneur Scientist Summit Forum
- Shengnuo Biotech’s delegation took part in the CMC Industry Chain Summit Forum with innovative peptide drug CDMO services
The 2021 China Pharmaceutical CMC Industry Chain Technology Exchange and Entrepreneur Scientist Summit Forum will be held in Guangzhou from May 24 to May 25 to provide enterprises with a comprehensive exchange platform to showcase their professional technology and high-quality products. Chengdu Shengnuo Biotech was invited to participate in this forum.
The full name of CMC is Chemical Manufacturing and Control, including production process, impurity research, quality research and stability research, etc., that is, the pharmaceutical research part. Pharmaceutical research materials are a very important part of the drug application materials.
2021 China Pharmaceutical CMC Industry Chain Technology Exchange and Entrepreneur Scientist Summit Forum
This forum invited 108 experts from the pharmaceutical CMC industry chain as sharing guests to build a professional high-end cooperation and exchange platform in Huacheng Guangzhou. As a member of a biotechnology company, Chengdu Shengnuo Biotechtech has carried out a detailed display of its own technological achievements in the field of peptide drugs and the “Innovative Peptide Project CDMO”, which can provide professional peptide drug research and development services.
This forum focuses on technical exchanges, sharing and collisions. The sharing guests include many industry front-line experts, and the topics to be shared cover small molecule drugs and biomacromolecule drugs, including peptides, proteins, antibodies, glycans and nucleic acids and other fields. At the same time, the forum invited relevant scientists in the medical and biological field, industry leaders, fund venture capital experts, government leaders, and heads of platform-based enterprises to conduct roundtable forums and summit dialogues. The forum closely followed the current new technology of pharmaceutical preparations, deeply analyzed the strategic layout and resource integration, and carried out extensive and in-depth discussions with the participants.
Shengnuo Biotech’s delegation took part in the CMC Industry Chain Summit Forum with innovative peptide drug CDMO services
In the second round-table dialogue on the afternoon of the 26th, Chengdu Shengnuo Biotech Wen Yongjun and peer experts focused on the current opportunities and pain points of China’s development of innovative drugs, the direction of China’s biomedical R&D transformation and upgrading, and the development pattern of the domestic and foreign pharmaceutical CDMO industry. CRO A series of issues such as the opportunities and challenges of the company’s transformation to CDM0, intermediates, APIs, and the development of preparation companies were discussed. Wen Yongjun said that Shengnuo Bio will continue to deepen corporate cooperation with related industries, actively promote the effect of industry agglomeration, and seek high-quality development of the industry.